| Mrs Mopelola O Fatuga, | |
|
1005 Heathrow Ct, Wheaton, IL 60189-7774 | |
| (312) 523-4742 | |
| (630) 752-0980 |
| Full Name | Mrs Mopelola O Fatuga |
|---|---|
| Gender | Female |
| Speciality | Registered Nurse - Home Health |
| Location | 1005 Heathrow Ct, Wheaton, Illinois |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003280090 | NPI | - | NPPES |
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Mopelola O Fatuga, 1005 Heathrow Ct, Wheaton, IL 60189-7774 Ph: (312) 523-4742 | Mrs Mopelola O Fatuga, 1005 Heathrow Ct, Wheaton, IL 60189-7774 Ph: (312) 523-4742 |
News Archive
Three new studies presented today at the International Liver CongressTM 2014 have helped clarify the optimal use of combination therapy with peginterferon and nucleoside analogues (NUCs) to achieve the best treatment outcomes in patients with chronic hepatitis B (CHB).
With an ever-increasing volume of electronic data being collected by the healthcare system, researchers are exploring the use of machine learning—a subfield of artificial intelligence—to improve medical care and patient outcomes.
A new drug appears to help chronic myeloid leukemia patients who are out of treatment options after first- and second-line drugs have failed them or because their cancer cells have a mutation that makes them resistant from the start, researchers reported at the 52nd Annual Meeting of the American Society of Hematology.
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, obtained positive results from a recently completed Phase 2 study of LX4211 in patients with type 2 diabetes mellitus. LX4211 is a once-per-day, orally-delivered, small molecule drug candidate that inhibits the sodium-dependent glucose transporter 2 (SGLT2), lowering the accumulation of glucose in the body and reducing caloric load.
Lux Biosciences, Inc. today announced its submission of simultaneous regulatory filings to both the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) seeking marketing approval for its investigational drug LUVENIQ™ (LX211; oral voclosporin) for the treatment of noninfectious uveitis involving the intermediate or posterior segments of the eye.
› Verified 7 days ago
Emily Bernas, Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 111 N County Farm Rd, Wheaton, IL 60187 Phone: 630-682-7400 | |
Siomara Sotelo, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 1506 E Roosevelt Rd, Wheaton, IL 60187 Phone: 630-221-1400 | |
Mary Parker, Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 111 N County Farm Rd, Wheaton, IL 60187 Phone: 630-682-7400 | |
John Holanday, Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 2117 Belleau Woods Ct, Wheaton, IL 60189 Phone: 630-253-7183 | |
Laura Bobbitt, RN BSN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 111 N County Farm Rd, Wheaton, IL 60187 Phone: 630-682-7400 | |
Kelly Biallas Miksche, Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 111 N County Farm Rd, Wheaton, IL 60187 Phone: 630-682-7400 |